区分临床无肌病性幼年皮肌炎与幼年皮肌炎的特征
本研究比较了12例符合改良Sontheimer标准的临床无肌病性幼年皮肌炎(CAJDM)患者与60例匹配的符合Bohan和Peter标准的幼年皮肌炎(JDM)患者,发现CAJDM患者常携带抗p155/140(转录中介因子1)自身抗体,全身表现较少且接受治疗较少,多变量模型显示较低的骨骼评分和较少见的肌痛是区分两者的最重要因素。
要点
- CAJDM患者中75%携带抗p155/140(转录中介因子1)自身抗体。
- CAJDM患者肌肉、骨骼及总体临床评分均低于JDM患者。
- 多变量模型显示较低骨骼评分和较少肌痛是区分CAJDM与JDM的最重要因素。
核心结论
- CAJDM可能可与JDM区分,因其常携带p155/140(转录中介因子1)自身抗体、全身表现较少且接受治疗较少。
研究设计与样本
- 研究纳入12例(9例低肌病性、3例无肌病性)符合改良Sontheimer标准的CAJDM患者与60例匹配的符合Bohan和Peter标准的JDM患者,比较人口学、临床、实验室及治疗数据。
- 差异采用Fisher精确检验、Mann-Whitney检验、随机森林及逻辑回归分析评估。
主要发现
- 9例(75%)CAJDM患者有抗p155/140(转录中介因子1)自身抗体,1例(8.3%)有抗黑色素瘤分化相关基因5自身抗体,2例(16.7%)肌炎自身抗体阴性。
- CAJDM患者诊断时年龄更小,起病时常为轻度疾病,肌痛、关节炎、挛缩、钙质沉着、吞咽困难、腹痛和乏力较少见。
- CAJDM患者肌肉、骨骼及总体临床评分较低,血清肌酶升高较少见且峰值较低,接受药物数量少于JDM患者。
- 仅50%的CAJDM患者接受口服泼尼松,但最大剂量和治疗持续时间与JDM无差异。
- 中位随访2.9年时,CAJDM患者无功能残疾记录,无人出现无力、钙质沉着、间质性肺病或脂肪营养不良。
关键数值与推荐
- CAJDM诊断采用改良Sontheimer标准,JDM诊断采用Bohan和Peter标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We examined features of clinically amyopathic JDM (CAJDM), in which patients have characteristic rashes with little to no evidence of muscle involvement, to determine whether this is a distinct phenotype from JDM. METHODS: Demographic, clinical, laboratory and treatment data from 12 (9 hypomyopathic, 3 amyopathic) patients meeting modified Sontheimer criteria for CAJDM and from 60 matched JDM patients meeting Bohan and Peter criteria were examined. Differences were evaluated by Fisher's exact and Mann-Whitney tests, random forests and logistic regression analysis. RESULTS: Nine (75%) CAJDM patients had anti-p155/140 (transcriptional intermediary factor 1), one (8.3%) anti-melanoma differentiation-associated gene 5 autoantibodies and two (16.7%) were myositis autoantibody negative. CAJDM patients were younger at diagnosis and frequently had mild disease at onset. CAJDM patients had less frequent myalgias, arthritis, contractures, calcinosis, dysphagia, abdominal pain and fatigue. The muscle, skeletal and overall clinical scores were lower in CAJDM. Serum muscle enzymes were less frequently increased in CAJDM, and peak values were lower. CAJDM patients received fewer medications compared with JDM patients. Only 50% of CAJDM patients received oral prednisone, but the maximum dose and treatment duration did not differ from JDM. At a median follow-up of 2.9 years, CAJDM patients had no documented functional disability, and none developed weakness, calcinosis, interstitial lung disease or lipodystrophy. Multivariable modelling revealed a lower skeletal score and less frequent myalgias as the most important factors in distinguishing CAJDM from JDM. CONCLUSION: CAJDM may be distinguished from JDM, in that they often have p155/140 (transcriptional intermediary factor 1) autoantibodies, have fewer systemic manifestations and receive less therapy.
引用
- Mamyrova G, Kishi T, Targoff IN, et al. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis. Rheumatology (Oxford). 2018. PMID: 30016492. doi:10.1093/rheumatology/key190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。